Blog icon

14 July 2020 Partner Release

The partnership will draw on CSIRO's COVID-19 response, including expertise in building vaccine testing models, and data analysis to provide insights about emerging disease hotspots.

Australia has redirected nearly AUD45 million from our AUD298.5 million development program in Indonesia towards COVID-19 activities.

This new funding of AUD1 million (IDR9.7 billion) forms part of Australia's additional AUD21 million COVID-19 response package targeted at immediate health, humanitarian and economic recovery in Indonesia and will be used to partner with key Indonesian research institutions.

Australia's Ambassador to Indonesia Gary Quinlan said Australia is pleased to work with Indonesia to support partnerships that foster scientific collaboration on issues crucial to the response.

"The global pandemic has impacted Australia and our Indo-Pacific neighbours profoundly and managing the social, economic and health impacts of COVID-19 is now the over-riding challenge for our region," Mr Quinlan said.

Professor Amin Soebandrio, Chairman of the Eijkman Institute for Molecular Biology under the Indonesian Ministry of Research and Technology welcomed the announcement.

"The Eijkman Institute for Molecular Biology is working hard to help the Indonesian Government in the fight against COVID-19," Professor Soebandrio said.

"One of the tasks given to us is to create a vaccine development platform for COVID-19 and other future emerging infectious diseases. We welcome international collaborations such as CSIRO's presence and contribution within the Eijkman Institute's Expert Technical Advisory Panel."

Petrarca Karetji, Head of the United Nations Pulse Lab Jakarta (a joint data innovation facility of the United Nations and the Government of Indonesia also funded by the Australian Government) also welcomed the opportunity to work with CSIRO’s Data61 team.

"Partnering with CSIRO will enable us to provide decision makers with valuable real time insights and predictive capacity to help develop strong data-informed strategies to prepare for, combat and recover from current and future pandemics in Indonesia, and across the Indo-Pacific region," Mr Karetji said.

CSIRO Chief Executive Dr Larry Marshall said CSIRO is working with partners around the world to share its multidisciplinary response to the global crisis, from vaccine testing and manufacturing, to predictive analytics and genetics.

"CSIRO had been preparing for a pandemic because our global partnerships help us see the future – that preparation allowed us to hit the ground running with our COVID-19 response," Dr Marshall said.

"Partnering with our global neighbours is how we deliver the solutions from science the world needs, so partnering with Indonesia and other nations means we can learn from each other, better protect the health of our people, and tackle this global crisis together."

This funding builds on more than 40 years of engagement and partnership between Australian and Indonesian researchers to solve key challenges for our region.

Available for interview:

  • Dr Prasad Paradkar, CSIRO
  • Mahesh Prakash, CSIRO

This media release originally appeared here: Australia and Indonesia to Partner on COVID-19 Research


Work underway at the Eijkman Institute for Molecular Biology.
CSIRO will contribute the Eijkman Institute’s Expert Technical Advisory Panel to help create a vaccine development platform for COVID-19.
Eijkman Institute for Molecular Biology is working hard to help the Indonesian Government in the fight against COVID-19.

Contact us

Find out how we can help you and your business. Get in touch using the form below and our experts will get in contact soon!

CSIRO will handle your personal information in accordance with the Privacy Act 1988 (Cth) and our Privacy Policy.

First name must be filled in

Surname must be filled in

I am representing *

Please choose an option

Please provide a subject for the enquriy

0 / 100

We'll need to know what you want to contact us about so we can give you an answer

0 / 1900

You shouldn't be able to see this field. Please try again and leave the field blank.